Vertex Pharma bets on kidney disease treatment with $4.9 billion Alpine Immune deal
(Reuters) -Vertex Pharmaceuticals will buy Alpine Immune Sciences for about $4.9 billion in cash, gaining access to the biotech firm’s…
(Reuters) -Vertex Pharmaceuticals will buy Alpine Immune Sciences for about $4.9 billion in cash, gaining access to the biotech firm’s…
By Mike Scarcella (Reuters) – The U.S. Justice Department’s blockbuster case accusing Apple of unlawfully monopolizing the smartphone market was…
By Max A. Cherney SAN FRANCISCO (Reuters) – Meta Platforms unveiled details on Wednesday about the next generation of the…
By Medha Singh (Reuters) – Retail traders are piling into risky bets after recouping all the losses made in the…